What is the State-of-the-Art: RCTs in surgery for recurrent Ovarian Cancer

ESGO eAcademy, Andreas du Bois, 340885

Video abstract 3 - Laterally extended pelvic resection with complete resection of ureter and nephrectomy

ESGO eAcademy, Michal Zikan, 340880

Video abstract 2 - ID 848: Indocyanine green to assess vascularity of Bricker ileal conduit anastomosis during pelvic exenteration for recurrent cervical cancer

ESGO eAcademy, Nicolò Bizzarri, 340879

Video abstract 1 - ID 1021: V-Y flap reconstruction for vulvar cancer recurrence after primary radiotherapy

ESGO eAcademy, Sergi Fernandez, 340878

Pelvic exenteration-Out of the box

ESGO eAcademy, Gwenael Ferron, 340877

Pelvic reconstruction

ESGO eAcademy, Cagatay Taskiran, 340876

Best oral - late breaking abstracts 2 - Q&A

ESGO eAcademy, Faculty / Presenters, 343702

Real-world patterns of care and outcomes in patients with microsatellite-instability high tumors in advanced endometrial cancer in the United States

ESGO eAcademy, Prabhu Vimalanand, 343700

Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study

ESGO eAcademy, Ana Oaknin, 343699

Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative.

ESGO eAcademy, Stefan Kommoss, 343698

Molecular profiling of NSMP high-risk endometrial cancers of the PORTEC-3 trial – prognostic refinement and druggable targets

ESGO eAcademy, Lisa Vermij, 343697

State of the art 8: Major advances in gynaecological cancers 2021 - Discussion

ESGO eAcademy, Faculty / Presenters, 343694

Focus on novel therapy in gynaecological cancers

ESGO eAcademy, Domenica Lorusso, 343693

Immunotherapy: New era in the management of endometrial and cervical cancers

ESGO eAcademy, Mansoor Raza Mirza, 343692

Major advances in gynaecological cancers 2021. Improving the standard of care: "More is NOT better!" -

ESGO eAcademy, Antonio Gonzalez-Martin, 343691

Technique of the pelvic exenteration

ESGO eAcademy, Francesco Raspagliesi, 340875

Perspectives on robotic assisted surgery in Gynecology Oncology during Covid times

ESGO eAcademy, Faculty / Presenters, 340864

Tumour board 2: Management of gynaecological sarcomas - Q&A

ESGO eAcademy, Faculty / Presenters, 340853

Scientific session 10: Immune checkpoint inhibitors- ready for the prime time in endometrial and cervical cancers? - Discussion

ESGO eAcademy, Faculty / Presenters, 340845

ERAS and impact of evidenced-based medicine in modern ovarian cancer surgical care

ESGO eAcademy, Pedro Ramirez, 340860

Adjuvant treatment of uterine sarcomas and management of metastatic disease

ESGO eAcademy, Ronnie Shapira-Frommer, 340852

How to improve immunotherapy strategies in uterine cancers: combinations and beyond

ESGO eAcademy, Faculty / Presenters, 340844

Role of immunotherapy in advanced and recurrent cervical cancer

ESGO eAcademy, Domenica Lorusso, 350673

Hot topics of the gyanecological oncologist: summary of recommendations

ESGO eAcademy, Dimitrios Haidopoulos, 340859

Diagnosis and surgical treatment of endometrial stromal sarcoma and uterine adenosarcoma - Anything new?

ESGO eAcademy, Mehmet Mutlu Meydanli, 340851

Role of immunotherapy in advanced and recurrent cervical cancer

ESGO eAcademy, Domenica Lorusso, 340843

Role of immunotherapy in advanced and recurrent endometrial cancer

ESGO eAcademy, Ana Oaknin, 350672

Overview of the new ESGO perioperative guidelines for ovarian cancer surgery

ESGO eAcademy, Christina Fotopoulou, 340858

How to diagnose and manage uterine leiomyosarcoma?

ESGO eAcademy, Frederic Amant, 340850

Antibody Drug Conjugates in Treating Recurrent Ovarian Cancer: The Next Generation – A Focus on NaPi2b

ESGO eAcademy, Faculty / Presenters, 340834

State of the art 6: SLN in gynaecological tumours (State of the art 2021 and next steps) - Discussion

ESGO eAcademy, Faculty / Presenters, 340819

Scientific session 9: PARP resistance - how might this be avoided or overcome? - Discussion

ESGO eAcademy, Faculty / Presenters, 340833

How we can discuss palliation with our patients

ESGO eAcademy, Kristina Lindemann, 340826

SLN vulva update

ESGO eAcademy, Maaike Oonk, 340818

New options of therapy in patients resistant to PARPi

ESGO eAcademy, David Tan, 340832

Role of palliative surgery in ovarian cancer

ESGO eAcademy, Jalid Sehouli, 340825

SLN ultrastaging and management of ITC in uterine cancer

ESGO eAcademy, Nadeem R. Abu-Rustum, 340817

Chemotherapy options after progression to PARPi

ESGO eAcademy, Sandro Pignata, 340831

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 350675

SLN uterine cancer European perspective (anatomic and surgical aspects, implementation, learning)

ESGO eAcademy, Jan Persson, 340816

Scientific session 8: Palliative strategies to optimise care in gynaecological cancer - Q&A

ESGO eAcademy, Jalid Sehouli, 340822

Pro and cons of palliative chemotherapy in relapsed ovarian cancer

ESGO eAcademy, Nicoletta Colombo, 340824

Mechanisms of resistance to PARPi in ovarian cancer

ESGO eAcademy, Gourley Charlie, 340830

Presidential session and awards

ESGO eAcademy, Faculty / Presenters, 340811

Lifetime award (Editor's choice)

ESGO eAcademy, Ignace Vergote, 348203

Lifetime award

ESGO eAcademy, Ignace Vergote, 343688

Presidential lecture

ESGO eAcademy, Faculty / Presenters, 343687

Workshop: How to break bad news in gynae oncology - Recaps

ESGO eAcademy, Faculty / Presenters, 340804

State of the Art 5: Updated ESGO-ESTRO-ESP guidelines in endometrial cancer - Q&A

ESGO eAcademy, Nicole Concin, 340795

Communication in a team

ESGO eAcademy, Annette Hasenburg, 340803

First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer-Con

ESGO eAcademy, Jonathan Ledermann, 340810

ESGO ESTRO ESP Endometrial cancer guidelines: Advanced and relapsed disease

ESGO eAcademy, Domenica Lorusso, 340794

Early-stage disease and adjuvant treatment

ESGO eAcademy, Carien Creutzberg, 340793

Communication cards

ESGO eAcademy, Ico Toth, 340802

Debate 2: First-line maintenance with PARP inhibitors should be given to all patients with ovarian cancer - Pro/Con

ESGO eAcademy, Faculty / Presenters, 340805

ESGO-ESTRO-ESP guidelines in endometrial cancer.Surgery in endometrial cancer

ESGO eAcademy, Nicole Concin, 340792

ESGO-ESTRO-ESP guidelines in endometrial cancer. Risk group stratification: Molecular markers

ESGO eAcademy, Remi Nout, 340791

Tumour board 1: Rare cervical cancers - Discussion

ESGO eAcademy, Faculty / Presenters, 340782

How to break bad news in gynae oncology

ESGO eAcademy, Jalid Sehouli, 340801

ESGO-ESTRO-ESP guidelines in endometrial cancer. Risk group stratification: Pathological parameters

ESGO eAcademy, Xavier Matias-Guiu, 340790

Fertility sparing surgery in FIGO "IB2" cervical cancer

ESGO eAcademy, Lukas Rob, 340781

Video abstract 3 - Orthotopic neo-bladder creation after cervical cancer

ESGO eAcademy, Conde Ana, 340774

Video abstract 2: ID 827 - How to do retro-peritoneal en bloc posterior pelvic exenteration in advanced ovarian cancer: Hudson-Dellepiane procedure in 10 steps

ESGO eAcademy, Nicolò Bizzarri, 340773

Small cell cancer cervical cancer 2B

ESGO eAcademy, David Tan, 340780

Video abstract 1: ID 630 - Vesico-vaginal fistula repair in a case of cancer cervix: A robotic assisted technique

ESGO eAcademy, Shylasree TS, 340772

State of the art 4: Role of radiomics and novel imaging in gynaecological cancer - Q&A

ESGO eAcademy, Fagotti Anna, 340764

Tumour Board 14: Cervical cancer in pregnancy

ESGO eAcademy, Alexandros Rodolakis, 340779

Video session 1: Pelvic and vulva reconstruction - Q&A

ESGO eAcademy, Faculty / Presenters, 340771

What we can achieve with US in gynaecologic oncology. Ready for radiomics?

ESGO eAcademy, Daniela Fischerova, 340763

Vulva reconstruction techniques

ESGO eAcademy, Sven Mahner, 340770

Radiomics in gynaecological cancer: MRI, CT scan and PET

ESGO eAcademy, Andrea Rockall, 340762

Bowel reconstruction techniques

ESGO eAcademy, Christina Fotopoulou, 340768

Debate 1: Is it time to implement molecular classification in the management of endometrial cancer? - Q&A

ESGO eAcademy, Faculty / Presenters, 340756

Why should a medical oncologist care about the molecular subtype of their endometrial cancer patients?

ESGO eAcademy, Alexandra Leary, 340755

Why should staging be adapted based on the molecular endometrial cancer subtype?

ESGO eAcademy, Frederic Amant, 340754

Why should pathologists embrace the molecular endometrial cancer classification?

ESGO eAcademy, Tjalling Bosse, 340753

Eliminating cervical cancer - EUP vision

ESGO eAcademy, Chrysoula Zacharopoulou, 344365

Eliminating cervical cancer - WHO vision

ESGO eAcademy, Princess Nothemba Simelela, 344366

What does women´s health mean for women's cancer?

ESGO eAcademy, Jalid Sehouli, 344367

WHO Keynote session: Eliminating cervical cancer in the EU and beyond: A global engagement - Q&A

ESGO eAcademy, Marc Arbyn, 344369

State of the art 3: Treating gynaecological cancer in the elderly and frail population - Q&A

ESGO eAcademy, Faculty / Presenters, 340740

The medical oncologist´s perspective

ESGO eAcademy, Jonathan Ledermann, 340747

Scientific session 6: Role of extrabdominal surgery in ovarian cancer - Q&A

ESGO eAcademy, Faculty / Presenters, 340733

The gyneco-oncologist´s perspective

ESGO eAcademy, Fagotti Anna, 340746

Multisystem toxicity in the elderly and frail: What can we learn from the NASA countermeasures program?

ESGO eAcademy, Jessica Scott, 340739

2nd ESO Ovarian Cancer Observatory:The clinical genetist´s perspective

ESGO eAcademy, JUDITH BALMAÑA, 340745

Management of thoracic disease and abdominal wall metastases in ovarian cancer

ESGO eAcademy, Philipp Harter, 340732

2nd ESO Ovarian Cancer Observatory:The clinical scientist´s perspective

ESGO eAcademy, Gourley Charlie, 340744

Frail patients and surgery

ESGO eAcademy, Kristina Lindemann, 340738

2nd ESO Ovarian Cancer Observatory:The pathologist´s perspective

ESGO eAcademy, Xavier Matias-Guiu, 340743

Chemotherapy in vulnerable older patients with advanced ovarian cancer - the challenge of complexity

ESGO eAcademy, Gilles Freyer, 340737

Management of brain and extra-abdominal lymph node metastases in ovarian cancer

ESGO eAcademy, Giovanni Scambia, 340731

New Frontiers in Treating Metastatic Cervical Cancer From Revolutionary Molecules to Clinical Therapies

ESGO eAcademy, Faculty / Presenters, 340726

Efficacy of niraparib by timing of Surgery and residual disease: Post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

ESGO eAcademy, Roisin O’Cearbhaill, 343679

Scientific session 5: ESGO quality indicators in endometrial cancer surgery - Q&A

ESGO eAcademy, Jan Persson, 340721

Identifying truly „actionable“ alterations: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

ESGO eAcademy, Cristiana Sessa, 340718